Schmidt P J Investment Management Inc. lowered its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 5.6% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,013 shares of the biopharmaceutical company’s stock after selling 60 shares during the period. Schmidt P J Investment Management Inc.’s holdings in Regeneron Pharmaceuticals were worth $498,000 as of its most recent filing with the SEC.

Several other hedge funds have also modified their holdings of the stock. Thrivent Financial for Lutherans raised its stake in shares of Regeneron Pharmaceuticals by 6.5% in the fourth quarter. Thrivent Financial for Lutherans now owns 2,620 shares of the biopharmaceutical company’s stock valued at $962,000 after buying an additional 160 shares during the period. RMB Capital Management LLC raised its stake in shares of Regeneron Pharmaceuticals by 5.4% in the fourth quarter. RMB Capital Management LLC now owns 5,818 shares of the biopharmaceutical company’s stock valued at $2,136,000 after buying an additional 300 shares during the period. Perigon Wealth Management LLC raised its stake in shares of Regeneron Pharmaceuticals by 23.8% in the fourth quarter. Perigon Wealth Management LLC now owns 1,289 shares of the biopharmaceutical company’s stock valued at $488,000 after buying an additional 248 shares during the period. Teachers Advisors LLC raised its stake in shares of Regeneron Pharmaceuticals by 6.0% in the fourth quarter. Teachers Advisors LLC now owns 93,990 shares of the biopharmaceutical company’s stock valued at $34,503,000 after buying an additional 5,295 shares during the period. Finally, Kentucky Retirement Systems acquired a new stake in shares of Regeneron Pharmaceuticals during the fourth quarter valued at $2,014,000. Institutional investors and hedge funds own 66.87% of the company’s stock.

Shares of Regeneron Pharmaceuticals, Inc. (REGN) traded down 1.00% on Friday, reaching $515.92. 617,665 shares of the company were exchanged. The company has a market cap of $54.47 billion, a price-to-earnings ratio of 62.45 and a beta of 1.67. The company’s 50-day moving average price is $493.24 and its 200 day moving average price is $413.36. Regeneron Pharmaceuticals, Inc. has a 12 month low of $325.35 and a 12 month high of $543.55.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings results on Thursday, May 4th. The biopharmaceutical company reported $2.92 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.50 by $0.42. Regeneron Pharmaceuticals had a net margin of 19.34% and a return on equity of 22.99%. The firm had revenue of $1.32 billion during the quarter, compared to analyst estimates of $1.30 billion. During the same quarter last year, the business earned $2.57 EPS. The company’s revenue was up 9.8% compared to the same quarter last year. On average, equities research analysts expect that Regeneron Pharmaceuticals, Inc. will post $12.77 EPS for the current year.

ILLEGAL ACTIVITY WARNING: “Schmidt P J Investment Management Inc. Sells 60 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)” was posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this article on another domain, it was illegally copied and republished in violation of U.S. & international copyright laws. The legal version of this article can be accessed at https://www.thecerbatgem.com/2017/07/23/schmidt-p-j-investment-management-inc-sells-60-shares-of-regeneron-pharmaceuticals-inc-nasdaqregn.html.

Several analysts have recently weighed in on REGN shares. Robert W. Baird reiterated a “neutral” rating and set a $369.00 target price on shares of Regeneron Pharmaceuticals in a research report on Tuesday, March 28th. Leerink Swann set a $448.00 price target on shares of Regeneron Pharmaceuticals and gave the company a “buy” rating in a research report on Tuesday, March 28th. BMO Capital Markets restated a “hold” rating and issued a $412.00 price target (up from $408.00) on shares of Regeneron Pharmaceuticals in a research report on Tuesday, March 28th. UBS AG boosted their price target on shares of Regeneron Pharmaceuticals from $435.00 to $446.00 and gave the company a “buy” rating in a research report on Wednesday, March 29th. Finally, BTIG Research restated a “buy” rating and issued a $460.00 price target on shares of Regeneron Pharmaceuticals in a research report on Wednesday, March 29th. One research analyst has rated the stock with a sell rating, sixteen have given a hold rating and thirteen have given a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average target price of $467.38.

In other Regeneron Pharmaceuticals news, Director Michael S. Brown sold 3,000 shares of the firm’s stock in a transaction that occurred on Friday, May 12th. The shares were sold at an average price of $450.00, for a total transaction of $1,350,000.00. Following the completion of the transaction, the director now owns 3,000 shares in the company, valued at approximately $1,350,000. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP Neil Stahl sold 8,306 shares of the firm’s stock in a transaction that occurred on Thursday, June 22nd. The stock was sold at an average price of $532.55, for a total transaction of $4,423,360.30. Following the transaction, the executive vice president now owns 43,950 shares of the company’s stock, valued at approximately $23,405,572.50. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 59,396 shares of company stock valued at $28,484,734. Company insiders own 10.40% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN).

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Stock Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.